
## ARTICLE IN PRESS

Biochimica et Biophysica Acta xxx (2013) xxx-xxx





Contents lists available at ScienceDirect

### Biochimica et Biophysica Acta



journal homepage: www.elsevier.com/locate/bbagen

# Immune signal transduction in leishmaniasis from natural to artificial systems: Role of feedback loop insertion

### Q1 Milsee Mol, Milind S. Patole, Shailza Singh\*

4 National Centre for Cell Science, NCCS Complex, Ganeshkhind, Pune University Campus, Pune 411007, India

#### ARTICLE INFO

Received in revised form 31 July 2013

Article history:

Keywords:

Cross-talk

Signaling

Leishmania

ODE

Systems biology

Received 29 April 2013

Accepted 23 August 2013

Mathematical modeling

Available online xxxx

#### ABSTRACT

Background: Modulated immune signal (CD14-TLR and TNF) in leishmaniasis can be linked to EGFR pathway 22 involved in wound healing, through crosstalk points. This signaling network can be further linked to a synthetic 23 gene circuit acting as a positive feedback loop to elicit a synchronized intercellular communication among the 24 immune cells which may contribute to a better understanding of signaling dynamics in leishmaniasis. Methods: Network reconstruction with positive feedback loop, simulation (ODE 15s solver) and sensitivity anal-26 ysis of CD14–TLR, TNF and EGFR was done in SimBiology (MATLAB 7.11.1). Cytoscape and adjacency matrix were 27 used to calculate network topology. PCA was extracted by using sensitivity coefficient in MATLAB. Model reduc- 28 tion was done using time, flux and sensitivity score. Results: Network has five crosstalk points: NIK, IKB-NFKB and MKK (4/7, 3/6, 1/2) which show high flux and sen- 30 sitivity. PI3K in EGFR pathway shows high flux and sensitivity. PCA score was high for cytoplasmic ERK1/2, PI3K, 31 Atk, STAT1/3 and nuclear JNK. Of the 125 parameters, 20% are crucial as deduced by model reduction. 32 Conclusions: EGFR can be linked to CD14-TLR and TNF through the MAPK crosstalk points. These pathways may 33 be controlled through Ras and Raf that lie upstream of signaling components ERK ½ (c) and JNK (n) that have 34 a high PCA score via a synthetic gene circuit for activating cell-cell communication to elicit an inflammatory 35 response. Also a disease resolving effect may be achieved through PI3K in the EGFR pathway. 36 General significance: The reconstructed signaling network can be linked to a gene circuit with a positive feedback 37 loop, for cell-cell communication resulting in synchronized response in the immune cell population, for disease 38 resolving effect in leishmaniasis. 39

© 2013 Elsevier B.V. All rights reserved. 40

42

#### 44 43

5

6

7 8

10

11

13

16

17

18

19 20

21

**O11** 15

#### 45 1. Introduction

Human body has an amazing protective immune system, which
safeguards us from infections caused by bacteria, viruses, protozoans,
parasites and fungi as well as from tumors growing within the body.
The activation of different immune cells and molecular interaction

0304-4165/\$ – see front matter © 2013 Elsevier B.V. All rights reserved. http://dx.doi.org/10.1016/j.bbagen.2013.08.018 among them will decide the extent of protective function of the im- 50 mune system. The defense system comprises of an intricately woven 51 network of signaling molecules within and between the interacting im- 52 mune cells. These molecules and cells work in a concert ensuring appro-53 priate response in resolving a diseased state. Past research efforts using 54 powerful experimental approaches have identified a staggering number 55 and variety of molecules participating in these immune functions. 56 Among them are cytokines, cell surface receptors and adaptor proteins 57 with individual properties, mediating cellular interactions to mount a 58 precise immune response [1]. But the problem is not the sheer number 59 of components participating in the immune response, it is the interac- 60 tions between the molecular and cellular machinery that often makes 61 the system unpredictable (nonlinear), and it becomes even more intrigu- 62 ing with the operation of positive-negative feedback and feedforward 63 loops. 64

Mathematical and computational modeling in immunology is in- 65 creasingly playing a role in data interpretation and attempts to extract 66 general biological understanding, through a systems biology approach. 67 Listing down of components participating in a signaling pathway can 68 help engineer novel signaling pathways, by using repeated iteration of 69 pretested domains, modules and motifs allowing the signaling proteins 70 to be controlled in an increasingly predictable way. Thus integration of 71

Please cite this article as: M. Mol, et al., Immune signal transduction in leishmaniasis from natural to artificial systems: Role of feedback loop insertion, Biochim. Biophys. Acta (2013), http://dx.doi.org/10.1016/j.bbagen.2013.08.018

Abbreviations: CD 14, cluster determinant 14; TLR, toll like receptor; TNF, tumor necrotic factor; EGFR, epidermal growth factor receptor; ODE, ordinary differential equation; PCA, principal component analysis; NIK, NFkB-inducing kinase; MKK, mitogen kinase kinases; PI3K, phosphatidylinositol 4-phosphate 3-kinase; ERK, extracellular regulated MAP kinase; Atk, agammaglobulinemia tyrosine kinase; STAT, signal transducer and activator of transcription; NFkB, nuclear factor kappa B; JNK, Jun NH2-terminal kinase; MAPK, mitogen activated protein kinases; IL, interleukins; APCs, antigen presenting cells; IFN, interferon; NO, nitric oxide; ROS, reactive oxygen species; Th1/2, T helper cells 1/2; PMN, poly morphonuclear neutrophil; LCF, leucocyte chemotactic factor; LPG, lipo phosphoglycan; IRAK, IL1 receptor associated kinases; SOCS, suppressor of cytokine synthesis; TNF, tumor necrotic factor; TRAF, TNF receptor associated factor; TAK, TGFB activated kinase; TAB, TAK1 binding protein; PSA, parasite surface antigen; AMPs, antimicrobial (poly) peptides; PKC, protein kinase C; Ras, rat sarcoma; PP2A, protein phosphatase 2A; KEGG, Kyoto Encyclopedia of Genes and Genomes; INOH, Integrating Network Objects with Hierarchies; SBML, Systems Biology Markup Language; DAG, directed acyclic graph; FBA, flux balance analysis

Corresponding author. Tel.: + 91 20 25708296/95; fax: + 91 20 25692259. *E-mail addresses:* shailza\_iitd@yahoo.com, singhs@nccs.res.in (S. Singh).

2

## **ARTICLE IN PRESS**

synthetic biologic devices to a systems level understood biological
 process may help better gauge the kinetic and quantitative aspects of
 signaling dynamics [2].

This study exploits leishmaniasis as an infectious disease model system to show how approaches of systems biology can be useful in giving new insight in macrophage immune cell signaling by constructing *in silico* signaling network. Linking this signaling network to a logic based gene circuit via synthetic biology approach may activate and direct macrophages for triggering immune intercellular communication, for a disease resolving effect.

#### 82 1.1. Immune response in leishmaniasis

Q2 Leishmaniasis is one of the most neglected tropical diseases of the world; 350 million people are considered to be at risk of contracting 84 leishmaniasis, some 2 million new cases occur yearly, and it is endemic 85 in 88 countries. Treatment options are few and with the available 86 chemotherapeutics emergence of drug resistance is a serious concern 87 [3]. It is one of the most diverse and complex of all vector borne diseases, 88 caused by a kinetoplastid obligate intracellular protozoan parasite be-89 longing to the genus Leishmania, causing self-healing cutaneous lesions 90 91 to fatal visceral leishmaniasis. It has a distinct dimorphic life cycle: 92extracellular stage promastigotes multiply and develop within the digestive tract of sandfly, and intracellular amastigotes reside and mul-93 tiply within the phagolysosomal vacuoles of mammalian phagocytes. 94 When an infected sandfly bites a mammalian host, it injects metacyclic 95promastigotes into the skin where they are captured by phagocytic cells. 96 97 Inside the phagocytes promastigotes metamorphose to amastigotes that multiply and are eventually released within the extracellular space, 98 where they can be engulfed by another phagocytic cell or can be taken 99 in the blood meal by a sandfly, to begin a new cycle of infection [4]. 100

101 Current chemotherapeutics to treat leishmaniasis are the stan-102 dard pentavalent antimonials (meglumine antimonate and sodium 103 stibogluconate) that have been used as the first line of therapy for more than 60 years. Many drug repositioning efforts have shown Q3 that drugs like miltefosine (anti-cancer drug) and amphotericin 105B (fungicide) can be used effectively against Leishmania; similarly 106 107 paromomycin and pentamidine are also shown with anti-leishmanial activity. New drug discovery strategies have led to the discovery of 04 sitamaguine, 2-substituted guinolines, buparvaguone and derivatives, 109 and 8-aminoquinolines as potential antileishmanial drugs and are in 110 111 various stages of clinical trials in India and Kenya. Combination of chemotherapeutics (e.g. sodium stibogluconate and paromomycin) to 112 combat Leishmania has been implemented, which is a standard practice 113 in the treatment of infectious disease like tuberculosis, leprosy and 114 malaria [5]. Though there has been a substantial improvement in 115116 the way leishmaniasis is treated, there still remains the problem of development of drug resistant strategies evolving in the parasite, 117 which varies from species to species and host-parasite interactions. 118 Also, many endeavors have been made in search for a vaccine for 119 leishmaniasis and some have made it to the clinical trials like the 120 121 second-generation vaccine LEISH-F1 + MPL-SE of Reed and co-122workers, consisting of three recombinant Leishmania poly protein LEISH-F1 antigens (S. Reed, Personal communication, IDRI, Seattle, 123USA). Likewise, parasite surface antigen 2 (PSA-2) derived from leish-124manial antigens has been tested; however, promising findings from 125126animal models were overshadowed by mostly negative T cell responses in humans [6]. 127

Therefore, keeping these views in mind there is an urgent need to 128 look beyond chemotherapeutics, and bring about a radical change in 129the way leishmaniasis is treated and managed, not only to overcome 130the serious problem of drug resistance but also to lower the toxicity 131 effects. One such line of attack could be using strategies of synthetic 132biology through a systems based approach, and engineer new modular 133 systems with predicted behavior, through simple methods of genetic 134 135 recombination giving rise to an artificial system that has evolved from the natural system. Synthetic gene circuits have been developed 136 and applied to easy-to-manipulate bacterial [7], viral [8] and lower 137 eukaryotes like yeast [9] systems and applying these principles to the 138 more complex and evolved mammalian cells is gradually becoming 139 possible as assorted heterologous transcription control systems are 140 being assembled and reprogrammed [10,11]. In mammalian cells, 141 several transgene control mechanisms have been developed as assorted 142 heterologous transcription control systems are being assembled and 143 characterized; synthetic circuits can be applied to mammalian systems 144 like the tetracycline responsive [12], biotin-responsive elements [13], 145 arginine-responsive [14], or phloretin-responsive [15].

Similarly, a synthetic gene circuit can be designed considering the 147 murine experimental leishmaniasis model which suggests that protec- 148 tive immunity against the parasite is dependent on the development 149 of a Th1 cell mediated immune response which is characterized by 150 production of IL12 by APCs, IFN- $\gamma$  by CD4 + T cells and nitric oxide 151 (NO) and reactive oxygen species (ROS) by macrophages to eliminate 152 the intracellular parasites. Whereas disease progression is thought to 05 result from the induction of Th2 responses, characterized by release of 154 IL4 or IL10 by APC instead of IL12, leading to the priming of IL4 produc- 155 ing CD4 + T cells and resulting in alternatively-activated macrophages, 156 these become a favorable niche for the safe intracellular survival for 157 the parasite leading to the development of symptoms associated with 158 Leishmania infection. Thus in leishmaniasis, there exists a fine balance 159 between the Th1 (protective)/Th2 (susceptible) response, which ulti- 160 mately decides the fate of the disease [16]. The Th1/Th2 paradigm is 161 thought to occur in leishmaniasis due to the interaction of parasite's 162 proteins with the host immune signaling mechanisms, tipping the 163 scale towards a Th2 response. During infection with promastigotes 164 polymorphonuclear neutrophils (PMNs) are recruited to the site of in- 165 oculation in response to the chemokines produced by the infected tissue 166 and leucocyte chemotactic factor (LCF) by the parasite. The parasites are 167 phagocytosed by the PMNs, and they release IL8 amplifying the migra- 168 tion of PMNs to the site of infection. After ingestion, Leishmania survives 169 intracellularly in the PMNs and delays the spontaneous apoptosis of 170 PMNs, during which they release monocyte-attractant chemokine 171 MIP-1b recruiting monocytes to the site of infection who ingest the 172 Trojan horses i.e. the apoptotic PMNs that harbor viable parasites. 173 Uptake of apoptotic PMN silences the antimicrobial functions of macro- 174 phages and the parasites survive and multiply in them, thus gaining 175 entry in its host macrophage by using neutrophils as an intermediate 176 carrier [17]. 177

#### 1.2. Immune signaling pathways modulated by Leishmania

Though Leishmania is recognized by its pathogen associated mole- 179 cules like lipophosphoglycan (LPG) by toll like receptor (TLR)s [18], it 180 has the ability to counteract TLR detection by interfering with TLR 181 signaling and silencing the immune cell activation rendering them re- 182 fractory to subsequent TLR stimulation. LPG on binding to TLR2 induces 183 the expression and activation of the serine/threonine phosphatase PP2A 184 that acts on TLR cytoplasmic adaptor proteins like IRAK-1, MAPKs, and 185 IKB causing their inactivation leading to tolerance. The induction of 186 PP2A requires p38 and NF-KB, which are the downstream effector 187 MAPKs, in the TLR signaling [19]. Similar to induction of PP2A, Baldwin 188 et al. [20] have shown that LPG can induce the expression of suppressors 189 of the cytokine signaling (SOCS-1 and SOCS-3) family proteins. Srivastav Q6 et al. [21] have shown that the TLR2 mediated pathway is modulated by 191 the parasite through the inhibition of the IKK-NFKB and suppression of 192 IL12 and TNF- $\alpha$  production, by inducing the deubiquitinating enzyme 193 A20. It acts by inhibiting the association of TRAF6 with TAK-TAB com- 194 plex and thus impairing the recruitment of TRAF6 in TLR2 signaling. 195 LPG also blocks the production of NO and ROS by binding to the regula- 196 tory domain of PKC [22]. These evidences suggest that Leishmania 197 exploits host PP2A, SOCS and A20 to inhibit the TLR2 mediated 198 proinflammatory gene expression and escapes the immune responses 199

178

Please cite this article as: M. Mol, et al., Immune signal transduction in leishmaniasis from natural to artificial systems: Role of feedback loop insertion, Biochim. Biophys. Acta (2013), http://dx.doi.org/10.1016/j.bbagen.2013.08.018

Download English Version:

# https://daneshyari.com/en/article/10800225

Download Persian Version:

https://daneshyari.com/article/10800225

Daneshyari.com